Serious safety issue forces Novo Nordisk to hit pause on late-stage hemophilia trials

Novo Nordisk has halted one midstage and two late-stage tests of its bleeding disease drug concizumab after seeing blood clots in some patients.

Serious safety issue forces Novo Nordisk to hit pause on late-stage hemophilia trials
Novo Nordisk has halted one midstage and two late-stage tests of its bleeding disease drug concizumab after seeing blood clots in some patients.